Nanoparticles for the delivery of genes and drugs to human hepatocytes
- 29 June 2003
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 21 (8) , 885-890
- https://doi.org/10.1038/nbt843
Abstract
Hepatitis B virus envelope L particles form hollow nanoparticles displaying a peptide that is indispensable for liver-specific infection by hepatitis B virus in humans. Here we demonstrate the use of L particles for the efficient and specific transfer of a gene or drug into human hepatocytes both in culture and in a mouse xenograft model. In this model, intravenous injection of L particles carrying the gene for green fluorescent protein (GFP) or a fluorescent dye resulted in observable fluorescence only in human hepatocellular carcinomas but not in other human carcinomas or in mouse tissues. When the gene encoding human clotting factor IX was transferred into the xenograft model using L particles, factor IX was produced at levels relevant to the treatment of hemophilia B. The yeast-derived L particle is free of viral genomes, highly specific to human liver cells and able to accommodate drugs as well as genes. These advantages should facilitate targeted delivery of genes and drugs to the human liver.Keywords
This publication has 36 references indexed in Scilit:
- Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectorsBlood, 2003
- Gene therapy for SCID—a complication after remarkable progressThe Lancet, 2002
- Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivoBlood, 2002
- Viral Vectors Still Pack SurprisesScience, 2001
- Investigation of gene therapy beginsNature Biotechnology, 2000
- Gene Therapy Death Prompts Review of Adenovirus VectorScience, 1999
- Gene therapy - promises, problems and prospectsNature, 1997
- Human gene therapy — an immature genie, but certainly out of the bottleNature Medicine, 1996
- Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine)Vaccine, 1990
- Efficient expression of genetically engineered hepatitis B virus surface antigen P31 proteins in yeastGene, 1989